Since safe and effective IL-13 inhibiting drugs/therapies are already available (such as allergy/asthma treatments and recombinant viral vectors) [53,58], their repurposing could be a highly cost-effective solution in alleviating SARS-CoV-2-associated pathology. This evidence concerns the gene IL13 and allergic disease.